Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Ovid Therapeutics Inc. Common Stock

OVID

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Last trade $2.27
Day change -$0.13 (-5.42%)
Day range $2.17 – $2.46
Volume 1,616,006
Market cap $453M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$452.96M
Price / earnings
—
Price / book
2.28×
Price / sales
312.17×
EV / sales
302.65×
EV / EBITDA
-6.45×

Profitability

Earnings per share
-$0.23
Return on assets
-19.4%
Return on equity
-21.7%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
11.97×
Quick ratio
11.97×
Cash ratio
1.16×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$57.78M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for OVID, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$733K$0$718K$132K$6.27M$130K$76K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$733K$0$718K$132K$6.27M$130K$76K
Selling, general and administrative$6.67M$6.47M$6.67M$6.42M$6.79M$4.88M$6.02M$4.88M
Research and development$15.7M$9.96M$11.18M$6.59M$5.87M$6.47M$6.66M$5.92M
Total operating expenses$22.36M$16.43M$17.85M$13.01M$12.66M$11.35M$12.68M$10.8M
Operating income-$22.36M-$15.7M-$17.85M-$12.29M-$12.52M-$5.07M-$12.55M-$10.72M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$20.78M-$15.01M-$16.99M$9.66M-$12.16M-$4.68M-$10.24M-$9.25M
Income taxes$0$0$0$0$0$0$0$0
Net income-$20.78M-$15.01M-$16.99M$9.66M-$12.16M-$4.68M-$10.24M-$9.25M
Net income attributable to common shareholders-$20.78M-$15.01M-$16.99M$9.66M-$12.16M-$4.68M-$10.24M-$9.25M
EBITDA-$22.35M-$15.68M-$17.81M-$12.28M-$12.51M-$4.97M-$12.41M-$10.56M
Basic earnings per share-$0.10-$0.08-$0.12$0.12-$0.17-$0.06-$0.14-$0.13
Diluted earnings per share-$0.10-$0.08-$0.12$0.12-$0.17-$0.06-$0.14-$0.13

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates

Anika Therapeutics reported Q3 2026 earnings of $0.29 per share, beating consensus estimates of $0.17 by 70.59%, with revenues of $30.59 million exceeding expectations by 3.94%. The stock has gained 101.1% year-to-date, significantly outperforming the S&P 500's 7.4% gain. However, the company received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market.

GlobeNewswire Inc.

BIO-Europe 2026 to Convene Global Biopharma Decision-Makers in Cologne

BIO-Europe 2026 will host over 6,000 senior leaders from the global biopharma industry in Cologne, Germany, from November 9-11, 2026. The 32nd annual edition expands beyond partnering to become Europe's largest biopharma strategy forum, featuring seven integrated tracks covering regulatory, clinical, and manufacturing strategy, with focus on partnerships, innovation, and addressing industry challenges.

The Motley Fool

Here's Why Ovid Therapeutics Stock Popped Higher Today

Ovid Therapeutics stock surged 18% following positive Phase 1 data for OV329, a next-generation GABA-AT inhibitor for epilepsy. The drug showed no treatment-related adverse events at 7mg dose and no ophthalmic changes, addressing safety concerns with existing treatments. The company announced a $60M private placement to fund Phase 2 trials and expansion into other indications.

GlobeNewswire Inc.

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Ovid Therapeutics secured $60 million in private investment in public equity (PIPE) financing led by Point72, with participation from multiple hedge funds and asset managers. The company plans to use proceeds to expand development of OV329, a GABA-aminotransferase inhibitor, into tuberous sclerosis complex and infantile spasms indications, along with general R&D expenses.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.